Cases and Conversations™: Optimizing Outcomes in PV and ET—Evolving Standards, Symptom Management, and Therapeutic Innovation

Release Date: December 12, 2025

Expiration Date: December 12, 2026

Activity Overview

The treatment landscape for polycythemia vera (PV) and essential thrombocytopenia (ET) is rapidly evolving, with risk-adapted strategies guided by updated recommendations from the National Comprehensive Cancer Network (NCCN), European LeukemiaNet (ELN), and International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-T). The introduction of novel agents such as ropeginterferon alfa-2b, ruxolitinib, pelabresib, and bomedemstat—particularly in cases of hydroxyurea resistance or intolerance—adds further complexity to treatment decisions. While these therapies offer promise in improving hematologic control and symptom burden, clinician education is needed to support appropriate therapy selection, treatment sequencing, and the incorporation of molecular testing to guide care.

This Cases and Conversations™ activity features expert faculty discussing cases of PV and ET, highlighting relevant clinical data and guideline recommendations for the diagnosis and management of these myeloproliferative disorders.

This educational activity is an archive of the live virtual symposium held on November 12, 2025.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers involved in the treatment and management of PV and ET.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Interpret recent clinical trial data and guideline updates relevant to the treatment of PV and ET
• Apply evidence-based treatment strategies to newly diagnosed and previously treated patients with PV and ET
• Identify best practices for supportive care and symptom monitoring in patients with PV and ET

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.